10 completed, 7 unknown, 2 active not recruiting, 1 not yet recruiting. 8 Phase 3, 7 Phase 2, 3 Phase 1, 2 Not applicable, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Unknown 4, Active not recruiting 2, Completed 2 |
| Phase 2 | 7 | Completed 6, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 2 | Unknown 2 |
Follow Placebo 1: new trials by email Literature Review of Placebo 1 trials Research Report on Placebo 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Vitamin D and Branched-chain Amino Acids on Physical Performance and Biomarkers of Muscle Fatigue in Runners Training program, Branched-Chain Amino Acids, Vitamin D - Healthy Adult Male, Runners | Not applicable | Not yet recruiting | Pedro Julian Flores Moreno | 64 | 2026-01-01 | 2026-01-12 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 565 | 2025-03-20 | 2026-10-15 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 588 | 2025-01-31 | 2026-10-15 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1 - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 13 | 2024-03-15 | 2025-06-17 |
| Effects of Probiotics on Metabolic Syndrome ,Intestinal Microflora and SCFA. Probiotics 1, Probiotics 2, Probiotics 3 - Metabolic Syndrome | Not applicable | Completed | Glac Biotech Co., Ltd | 82 | 2021-08-01 | 2023-12-28 |
| A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding Esomeprazole 40mg, Ilaprazole Sodium, Placebo 1 - Stress Ulcer Bleeding | Phase 3 | Completed | Livzon Pharmaceutical Group Inc. | 449 | 2021-07-16 | 2023-05-03 |
| A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy Pregabalin, Acetaminophen, Placebo 1 - Postoperative Pain | Phase 2 | Completed | Nevakar, Inc. | 87 | 2020-07-28 | 2021-11-23 |
| Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease Otilimab, Placebo 1, Placebo 2 - Severe Acute Respiratory Syndrome | Phase 2 | Completed | GlaxoSmithKline | 1156 | 2020-05-28 | 2024-09-23 |
| Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg - Insomnia Disorder | Phase 2 | Completed | Idorsia Pharmaceuticals Ltd. | 360 | 2016-10-04 | 2020-04-13 |
| Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion Tramadol, Celecoxib, Placebo 1 - Pain | Phase 4 | Unknown | Cairo University | 210 | 2016-07-01 | 2019-04-08 |
| Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI DHEA, Growth hormone, Placebo 1 - Subfertility | Phase 4 | Unknown | Cairo University | 230 | 2016-06-01 | 2018-01-03 |
| A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome) Yiqi prescription, Huoxue prescription, Buyang huanwu decoction - Ischemic Heart Failure | Phase 2 | Unknown | Zhu Mingjun | 180 | 2016-06-01 | 2016-08-23 |
| Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response DHEA, Growth Hormone-Releasing Hormone, Placebo 1 - Subfertility | Phase 3 | Unknown | Cairo University | 210 | 2016-06-01 | 2016-07-06 |
| Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women Celecoxib, Tramadol, Placebo 1 - Hysteroscopy | Phase 3 | Unknown | Cairo University | 210 | 2016-06-01 | 2016-07-06 |
| Tramadol Versus Celecoxib for Reducing Pain During Operative Office Hysteroscopy Celecoxib, Tramadol, Placebo 1 - Hysteroscopy | Phase 3 | Unknown | Cairo University | 210 | 2016-06-01 | 2016-07-06 |
| Monotherapy With Rapamycin in Long-standing Type 1 Diabetes rapamycin, Vildagliptin, Placebo 1 - Diabetes Mellitus, Type 1 | Phase 2 | Completed | Piemonti Lorenzo | 55 | 2016-05-01 | 2020-11-04 |
| Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? Fluoxetine, Combined oral contraceptives, Placebo 1 - Premenstrual Syndrome | Phase 3 | Unknown | Cairo University | 300 | 2015-10-01 | 2016-07-06 |
| An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients VTP-43742, Placebo 1, Placebo 2 - Psoriasis | Phase 1 / Phase 2 | Completed | Vitae Pharmaceuticals Inc., an Allergan affiliate | 74 | 2015-08-01 | 2018-10-30 |
| Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome Yasmin, Calver, Placebo 1 - Premenstrual Syndrome | Phase 3 | Completed | Beni-Suef University | 210 | 2014-05-01 | 2015-08-11 |
| A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453 LFX453 H1, LFX453 L1, LFX453 H2 - Healthy | Phase 1 | Completed | Novartis Pharmaceuticals | 41 | 2014-01-01 | 2015-05-15 |
Dermatitis (2) · Hidradenitis (2) · Hidradenitis Suppurativa (2) · Infertility (2) · Premenstrual Syndrome (2) · COVID-19 (1) · Coronary Artery Disease (1) · Coronavirus Infections (1) · Diabetes Mellitus, Type 1 (1) · Metabolic Syndrome (1) · Pain (1) · Pain, Postoperative (1) · Psoriasis (1) · Severe Acute Respiratory Syndrome (1) · Sleep Initiation and Maintenance Disorders (1)
Cairo University (6) · Novartis Pharmaceuticals (3) · Beni-Suef University (1) · Glac Biotech Co., Ltd (1) · GlaxoSmithKline (1) · Idorsia Pharmaceuticals Ltd. (1) · Livzon Pharmaceutical Group Inc. (1) · Nevakar, Inc. (1) · Pedro Julian Flores Moreno (1) · Piemonti Lorenzo (1) · University of Michigan (1) · Vitae Pharmaceuticals Inc., an Allergan affiliate (1) · Zhu Mingjun (1)
Egypt (7) · United States (7) · Mexico (4) · Spain (4) · Argentina (3) · Canada (3) · China (3) · Colombia (3) · Germany (3) · Italy (3) · Poland (3) · United Kingdom (3) · Belgium (2) · France (2) · Greece (2)
AbdelGany M Hassan (3) · AbdelGany M Hassan, MRCOG, MD (1) · Abdelgany M Hassan, Lecturer (1) · Chatkaew Pongmala, PhD (1) · Emanuele Bosi, MD (1) · Hsieh-Hsun Ho, Ph. D. (1) · Li Bin (1) · Lorenzo Piemonti, MD (1) · Nesreen A Shehata, Lecturer (1) · Pedro J Flores Moreno, Doctor of Medical Sciences (1) · Richard Gregg, MD (1)
PMID 23741058, PMID 26808666, PMID 31953863, PMID 33124663, PMID 37477771, PMID 37526060, PMID 39046973, PMID 39175547
U01AG061393 (1)